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associated with a decreased in receipt of Tx2 and TxS, though this was not 
statistically significant for TxS. CONCLUSIONS: Surgery of the primary tumor 
site and marital status were the most significant clinical variables predicting 
whether elderly beneficiaries proceed to Tx2. Surgery of the primary site was 
only statistically significant for predicting receipt of TxS. Increased age, less than 
6 months of state buy-in, and SEER-registry site were associated with decreased 
receipt of Tx2 and TxS.  
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STUDY OF THE TREATMENT PATTERNS IN METASTATIC BREAST CANCER 
PATIENTS IN A TERTIARY CARE HOSPITAL  
Sandeep A, Singh K, Sreedharan N, Thunga G, Kunhikatta V 
Manipal University, Manipal, India  
OBJECTIVES: To evaluate the clinico-pathological characteristics and treatment 
pattern in metastatic breast cancer (MBC) in tertiary care hospital. METHODS: A 
retrospective study was conducted using patient medical records diagnosed with 
metastatic breast cancer from January 2006 to December 2010 and were analyzed 
for clinico-pathological characteristics and treatment patterns. Demographic 
data along with socio-family history, hormonal receptor status, HER2/neu status, 
menopausal status, distant metastasis and treatment were recorded. RESULTS: 
The study included 152 MBC patients, which showed that the majority was seen 
in age-group 25 to 50 years, and the number of postmenopausal women was the 
most observed. Among them there was equal distribution of both estrogen 
receptor (ER) positive and negative patients, while progesterone receptor (PR) 
negative patients were more when compared to positive. HER2/neu status was 
available in 74 patients, among them 32.4% were strongly positive, 35.1% 
patients were weakly positive and 32.4% were negative. Reports on organ 
metastasis were available for 146 patients, among them majority (37.1%) had 
bone metastasis followed by liver metastasis (19.8%). The treatment of MBC 
mainly included systemic chemotherapy and/or hormonal therapy. Palliative 
radiotherapy was given to 59.2% of patients. Anthracycline based 
chemotherapeutic regimens (AC, FAC, CEF) were prescribed the most common 
(88.9 %). Taxanes and capecitabine were prescribed as second line agents. 
However, aromatase inhibitors (1 mg once daily anastrazole, 2.5 mg once daily 
letrozole, and 25 mg once daily exemestane) were prescribed mainly as 
sequential or extended therapy. Bisphosphonate (monthly 4mg zolendronic acid) 
were prescribed among 30.7% of patients. The symptomatic treatments included 
opiates, antiematics, dexamethasone, antidepressant, laxatives, lidocaine, iron 
and calcium supplements. CONCLUSIONS: This study highlights the 
epidemiological, clinico-pathological characteristics of MBC and its treatment 
pattern in a tertiary care hospital in South India.  
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OBJECTIVES: Evidence supporting the use of adjuvant radiation therapy (ART) 
versus salvage RT (SRT) following prostatectomy in prostate cancer patients with 
high-risk disease is inconclusive. We sought to compare and contrast US and 
Italian Radiation Oncologists (RO) beliefs and practices on the use of ART and 
SRT in the treatment of prostate cancer following prostatectomy. METHODS: A 
34-question, web-based survey on post-prostatectomy prostate cancer ART and 
SRT treatment attitudes was distributed to US and Italian RO. Survey invitations 
were e-mailed to a sample of 926 US RO selected from the American Society for 
Radiation Oncology membership directory, and to all 716 Italian RO listed in the 
Italian Association of Radiation Oncology roster. Bivariate, chi-square analyses to 
compare US and Italian RO responses on ART and SRT beliefs and practices were 
performed. RESULTS: The US survey had 218 respondents (24% response rate), 
while the Italian survey had 154 respondents (21.5% response rate). Both US and 
Italian RO routinely recommend ART, but more US than Italian RO would initiate 
ART based solely on adverse pathological features in the prostatectomy 
specimen (79.4% vs. 68.4%, p<0.05). 70% US RO believed ART improves survival 
outcomes compared to 35.5% Italian RO (p<0.05). A striking difference in ART use, 
timing, dosage, and technique was found between Italian and US RO. More US 
RO would initiate salvage therapy based on any detectable PSA compared to 
Italian physicians (36.8% vs. 11.3%, p<0.05); Italian RO, in contrast, were more 
likely than US OR to initiate SRT upon higher PSA levels. CONCLUSIONS: Much 
variation is seen between US and Italian RO in regards to use of ART and SRT in 
prostate cancer patients after prostatectomy. More clinical studies should be 
undertaken in order to provide better evidence on ART versus SRT use in clinical 
practice.  
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OBJECTIVES: There is limited up-to-date available data examining the real-world 
treatment practices of prostate cancer (PC). The primary objective of this study is 
to describe treatment patterns, as well as resources utilization for PC in 
Argentina during 2012. METHODS: An in-depth face to face survey was 
conducted. Eligibility criteria included: oncologist, urologist or uro-oncologist; 
clinical experience in oncologic treatment of PC, including hormonal therapy; 
minimum patient volume of 30 PC patients at the moment of the enrollment in 
the survey; have high reputation as key opinion leaders. Results were analyzed 
and weighted according to the volume of patients each physician attended. 
RESULTS: Ten physicians (80% oncologist, 10% urologist, 10% uro-oncologist), 
mainly from the private sector (79% vs. 21%), with an average of 22 years of 
experience and currently treating an average of 44 patients were interviewed. 
The most common reason for consultation with the specialist was an abnormal 
PSA result. A total of 40% of patients were diagnosed with metastatic PC and 
immediately after, androgen deprivation therapy was started. In patients with 
localized PC, most doctors take patient’s preference into account (75% of their 
patients) in the choice of the treatment, and as the risk increased, radical 
prostatectomy was more commonly used. The most common treatment pattern 
in hormone therapy was the combination of a GnRH analogue and 
antiandrogens. In castration resistant PC, docetaxel is the most common 1st line 
therapy and mitoxantrone the 2nd line, followed by abiraterone. Health care 
resource utilization such as blood tests/year (complete blood count, blood 
chemistry, functional liver tests, PSA), some imaging tests/year, specialist visits 
and hospitalizations increases as disease progresses. CONCLUSIONS: Treatment 
pattern of PC in Argentina follow International Guidelines, and resource 
utilization increases as the disease progresses.  
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OBJECTIVES: Examine the associations between severity of chronic kidney 
disease (CKD) in patients with Type 2 diabetes, the probability of being 
hospitalized, and hospital length of stay (LOS). METHODS: This study utilized 
data from Humedica electronic medical records, captured in the period January 
1, 2007 through September 30, 2011. Patients eligible for this study were 
diagnosed with both CKD (ICD-9-CM 585.1-585.6) and Type 2 diabetes, and aged 
≥21yrs as of September 30, 2011. Logistic regression analyzed the relationship 
between CKD severity and the probability of hospitalization, while a negative 
binomial regression examined the relationship between CKD severity and 
hospital LOS. All analyses controlled for patient demographic characteristics, 
baseline antidiabetic therapy, baseline HbA1c levels, patient general health, and 
comorbidities. RESULTS: 3,406 individuals met the inclusion criteria: 687 with 
mild (ICD-9 585.1, 585.2; 1,981 moderate (585.3); and 425 severe CKD (585.4, 585.5); 
313 patients had end stage renal disease (ESRD) (585.6). Generally, patients with 
severe CKD or ESRD, compared to mild/moderate CKD, were more likely to be 
African-American, reside in the Midwest or South, have Medicaid insurance or 
be uninsured, and have received a prescription for insulin at baseline. Further, 
such patients were less likely to have commercial insurance, “good” glycemic 
control (HbA1c ≤7), or be using an oral antidiabetic therapy at baseline. Adjusted 
Odds Ratios (OR) showed that, compared to mild CKD, both severe CKD and ESRD 
were associated with a significantly higher likelihood of hospitalization in the 2 
year post index date (Severe: OR=2.040, 95% CI 1.531 – 2.720; ESRD: OR=2.910, 95% 
CI 2.071 – 4.088). Similarly, moderate CKD, severe CKD and ESRD were asso-
ciated with significantly longer LOS compared to mild CKD (Moderate: 
Coefficient=0.2431, P=0.0259; Severe: Coefficient=0.8081, P<0.0001; ESRD: 
Coefficient=1.1237, P<0.0001). CONCLUSIONS: As severity of CKD increases in 
patients with type 2 diabetes, the likelihood of hospitalization increases as does 
the need for inpatient resource utilization.  
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Lin PJ, Cohen JT, Winn A, Kent DM, Neumann PJ 
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OBJECTIVES: Greater comorbidity burden is correlated with poor patient 
outcomes among individuals with diabetes, but which condition clusters are 
most prevalent remains unclear. By identifying the most common multiple 
chronic condition (MCC) patterns, this study could help prioritize comorbidities 
to be addressed by clinical guidelines. METHODS: We conducted cross-sectional 
analysis of the 2008-2012 Humedica dataset containing information from 
electronic health records, encounter data, and lab values supplied by provider 
networks across the U.S. Our cohort included adults (aged ≥18 years) with type 2 
diabetes and at least 24 months of ambulatory and hospital data (n=162,332). Of 
the 14 comorbidities listed in the 2012 American Diabetes Association guidelines, 
we selected the eight conditions that each affected ≥10% of the patients and 
analyzed the most common patterns of MCCs by age group. RESULTS: 89.1% of 
diabetes patients had at least one comorbidity and 40.9% had three or more. 
Conditions with a prevalence rate ≥10% included hypertension (74.7%), 
hyperlipidemia (65.8%), coronary artery disease (CAD, 17.7%), cancers (17.1%), 
COPD/asthma (14.2%), arthritis (14.0%), chronic kidney disease (CKD, 12.0%), and 
depression (11.4%). The leading combination was hypertension and 
hyperlipidemia only, accounting for 21.1% of the population, followed by 
hypertension only (10.9%), hyperlipidemia only (5.0%), and the combination of 
hypertension and hyperlipidemia plus CAD (4.7%). Older adults (≥65 years) were 
more likely than younger adults (<65 years) to have all comorbidities except 
depression (7.6% vs. 10.1%, p=<0.0001), though the condition rankings were 
similar in both groups. CONCLUSIONS: Diabetes patients have substantial 
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comorbidities but the patterns vary considerably across patients. Although most 
diabetes guidelines address co-management of hypertension and 
hyperlipidemia, this MCC subgroup accounts for only one-fifth of patients. The 
development of evidence-based strategies to manage MCCs would help 
physicians and patients prioritize therapies and goals.  
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OBJECTIVES: To assess the clinical characteristics and economic burden of  
type-2 diabetes patients in the U.S. veteran population METHODS: A 
retrospective database analysis was performed using the Veterans Health 
Administration (VHA) Medical SAS Datasets from October 1, 2005 to May 31, 2012. 
All U.S. veteran beneficiaries diagnosed with type-2 diabetes were identified 
using International Classification of Disease 9th Revision Clinical Modification 
(ICD-9-CM) diagnosis code 250.x0 or 250.x2. Comorbidities and other clinical 
conditions were examined for the 12-month baseline period. Health care 
resource utilization and costs were assessed for the 12-month follow-up period. 
Descriptive statistics were calculated as means ± standard deviation  
and percentages to measure comorbidities, laboratory results, costs, and 
utilization distribution within the sample. RESULTS: A total of 741,406 veterans 
were identified as diagnosed with Type 2 diabetes. Of these patients, 18.77%  
had glycated hemoglobin (HbA1c) test results ≥7% and 27.21% had abnormal 
serum creatinine results. 62.71% of patients were obese with a body mass index 
(BMI) of ≥30. The most common comorbidities were unspecified essential 
hypertension (21.62%), other and unspecified hyperlipidemia (6.75%) and post-
traumatic stress disorder (5.15%). After examining treatment within 60 days of 
disease identification, simvastatin was the most commonly prescribed 
medication (21.62%), followed by metformin hydrochloride (27.43%). Insulin was 
also among the top 10 treatments with 10.67% of patients prescribed this 
medication. The percentage of patients with follow-up outpatient visits was 
99.80%, which translated into $6,531 average outpatient costs. The percentages 
of inpatient (13.21%), emergency room (16.94%), physician office (99.76%) and 
pharmacy visits (90.33%) were also calculated for diabetes patients. 
CONCLUSIONS: Obesity may play an important role in patients' development of 
diabetes since two-thirds of studied patients were obese prior to disease 
identification. Hypertension may also be an associated risk factor that should be 
further evaluated.  
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OBJECTIVES: The ADA/EASD guidelines suggest the management and treatment 
of type 2 diabetes mellitus (T2DM) can be impacted by many factors such as age, 
comorbidities, hypoglycemia risk, and treatment adherence. Understanding  
how the T2DM disease burden differs across race/ethnic groups may aid  
in individualization of treatment. METHODS: Using data from the 2011 patient-
reported US National Health and Wellness Survey (NHWS), we characterized the 
T2DM population by profiling patients by race/ethnicity (White, African 
American [AA], Hispanic, or Other). NHWS results were stratified, then weighted 
and projected to reflect the demographic composition of the total adult 
population (based on Census data for gender, age, race/ethnicity, and 
educational attainment). RESULTS: Of the total 7,828 patients with T2DM, 75.8% 
were White, 11.4% were AA, 6.7% were Hispanic, and 6.1% were Other (includes 
Asian American and American Indian). The top 3 comorbidities per group  
were the same for the 3 predominant groups: hypertension (62% Whites, 64% 
AAs, 55% Hispanics), high cholesterol (66% Whites, 58% AAs, 57% Hispanics), and 
pain (55% Whites, 50% AAs, 51% Hispanics). However, significantly more Whites 
reported high cholesterol than AAs and Hispanics (P=0.002 and P=0.001, 
respectively). Sixty three to seventy nine percent of White, AA, and Hispanic 
patients with T2DM reported body mass index (BMI) ≥30 kg/m2; <10% of  
all patients reported BMI <25 kg/m2. Furthermore, Hispanics reported lower 
medication adherence than Whites (57.4% vs 65% adherent; P=0.008); adherence 
among AAs was 63%. Hypoglycemia was reported by 54% of Hispanics, 51%  
of Whites, and 49% of AAs. CONCLUSIONS: Understanding the characteristics of 
patients with T2DM by race/ethnicity can provide insights on the types  
of diabetes management challenges that different patient populations may  
face. These observations may encourage providers to engage minority 
populations in their health care management and tailor education to the 
individual.  
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OBJECTIVES: For insulin-treated patients with type 2 diabetes mellitus (T2DM), 
disposable pen may facilitate insulin administration compared to traditional 
vial/syringe. This study compared real-world outcomes of insulin glargine (GLA) 
administered via disposable pen versus vial/syringe injections among Medicaid 
T2DM patients. METHODS: Using 2007-2010 claims data from the 
MarketScan®Medicaid database, this retrospective study examined 1-year follow-
up outcomes among adult T2DM patients who were insulin-naive and initiated 
GLA via disposable pen (Pen Initiators, PI) or vial/syringe (Vial Initiators, VI), or 
GLA users continuing vial/syringe (Vial Continuers, VC) or switching to 
disposable pen (Pen Switchers, PS). Propensity-score matching was used to 
control for differences in baseline characteristics between PI and VI cohorts, and 
PS and VC cohorts, with each pen user matched to ≤2 vial users. Endpoints 
included 1-year treatment persistence and adherence, hypoglycemia, and health 
care costs. RESULTS: There were 2594 matched patients from 7 states and 2 
managed care plans in the insulin-naive cohorts (PI: n=983, VI: n=1,611; mean 
age 56 years, 65% female) and 2237 matched patients in the insulin-experienced 
cohorts (PS: n=783, VC: n=1454; mean age 52 years, 66% female). Compared with 
their respective matched cohorts, pen cohorts were significantly more 
treatment-persistent (PI: 49.2% vs. VI: 40.8%; PS: 45.6% vs. VC: 36.7%; both 
P<0.001) for longer time (276 vs. 247 and 257 vs. 236 days; both P<0.001). Similar 
numbers of patients had hypoglycemia among the insulin-naive (P=0.153) and 
insulin-experienced cohorts (P=0.164). Although pen users had significantly 
higher study drug costs than vial users (P<0.001), total health care costs were 
comparable (PI: $15,151 vs. VI: $15,994; P=0.458, and PS: $22,441 vs. VC: $22,403; 
P=0.984) due to an offset of medical costs. CONCLUSIONS: This real-world study 
suggests that, among Medicaid T2DM patients treated with GLA, use of 
disposable pen provides a beneficial effect of achieving better persistence 
without increasing overall health care costs.  
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OBJECTIVES: Patients with type-1 diabetes (T1D) can either use multiple daily 
injections or insulin pump therapy (IPT) to achieve glycemic control. However, 
there is a lack of real-world data on the differences in these treatment options, 
particularly as they relate to effectiveness. The objective of this study was to 
investigate the relationship between IPT and HbA1c among patients with T1D. 
METHODS: Data from unique respondents from the 2009-2012 U.S. National 
Health and Wellness Surveys were used. Among respondents who reported a 
diagnosis of T1D and reported using insulin, those who reported using IPT were 
compared with those who were not using IPT on reported HbA1c levels using an 
ordered logistic regression model controlling for sociodemographic and health 
history differences. RESULTS: A total of 1833 patients reported being diagnosed 
with T1D and were currently using insulin. Of these patients, 495 reported using 
IPT (27.0%). Patients using IPT had been diagnosed with T1D for longer (26.8 vs. 
21.1 years) and were significantly more likely to be female (53.1% vs. 42.5%), be 
non-Hispanic white (85.9% vs. 68.3%), have an annual household income of $75K 
or more (28.3% vs. 19.2%), and possess health insurance (95.8% vs. 84.5%) (all 
p<.05). Patients using IPT also reported significantly lower levels of HbA1c (7.2% 
vs. 7.5%, p<.05). Adjusting for sociodemographic and health history differences, 
patients using IPT were significantly less likely to report HbA1c levels 9% or more 
(b=-0.80, OR=0.45, p<.05). CONCLUSIONS: Although T1D patients with greater 
health care access were more likely to use IPT, even after adjusting for these 
differences, a significant effect of IPT was observed on HbA1c. These results 
suggest that IPT may be associated with greater real-world effectiveness, though 
additional research is necessary.  
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OBJECTIVES: To perform a meta-analysis of the clinical and biochemical 
outcomes of N-Acetyl Cysteine (NAC) in women with polycystic ovary syndrome 
(PCOS). METHODS: Systematic review of pertinent studies was conducted by 
using bibliographic databases such as MEDLINE (Ovid), CENTRAL, EMBASE and 
PsycInfo(inception to Nov 2012). References of selected articles were either hand-
searched and by using PROQUEST and Web of Science. The review included 
randomised controlled trials with women participants having PCOS and 
undergoing treatment with NAC alone or in combination with ovulation 
induction methods like clomiphene citrate (CC) or gonadotropin injections, or in 
vitro fertilization (IVF). RESULTS: Out of 182 retrieved reports, eight studies (900 
women) were included. Three studies compared NAC (n=179) to metformin 
(n=177) while five studies compared NAC (n=272) to placebo (n=269). Compared 
to placebo, NAC improved pregnancy rate (pooled odds ratio, OR: 3.97, 95%  
CI: 2.07, 7.59, 3 trials, 377 women, P<0.0001; I2: 53%), ovulation rate (OR: 4.49, 95% 
CI: 2.86, 7.04, 3 trials, 353 women, P<0.0001; I2: 85%) and live birth rate (OR: 3, 95% 
CI: 1.05, 8.60, 1 trial, 60 women, P=0.04). However, compared to metformin, NAC 
did not improve pregnancy rate, resumption of menstruation cycle, body mass 
index or testosterone level. NAC was signifianctly associated with lower 
ovulation rate (OR: 0.13, 95% CI: 0.08, 0.22, 2 trials, 253 women, P<0.0001; I2: 0%) 
compared to metformin. On the other hand, compared to NAC, metformin 
improved glucose and insulin resistance profiles. Also, when used alone or in 
combination with clomiphene, NAC did not significantly improve the 
anthropometric characteristics, testosterone levels, and lipid profiles compared 
to placebo and metformin. CONCLUSIONS: NAC was associated with improved 
clinical pregnancy but there was limited evidence that NAC improved live birth 
rates alone or in combination with clomiphene. Given the quality of studies, 
